Feeks Tom W? Supportive? Is that what you mean? If so its time to worry! No what I meant was that even though Tom was being critical by talking about Eden needing a placement, in fact what has previously happened from what I understand is that in Sipcams case have received cash and a supportive alliance in the process which helps them commercialise there technology at a faster rate and to a wider market. So I get that Tom has been and continues to be a critic, the plain truth is that if there is a placing it is likely to be with a company that will enhance Edens opportunities and give them cash which in the end will be a positive move. So what I'm saying is although Tom puts a negative spin on everything a quick look at what actually has occurred is that each placing has materially strengthened Edens position for the longterm, so he's being positive without even being aware of it. Maybe he's being ironic. Looking at the desperate way his website is attempting to pull in new readers It looks more like he will need a bucket shop placing sooner than any of the companies he covers. More irony there I think.
I'm slightly surprised and that he's become supportive all of a sudden. I'm not completely opposed to the idea considering the last too placings have been very positive for Eden and involved strategic partners, one being Sipcam who have a global footprint which will help Eden role out it's products.
No I meant it more like be diplomatic and don't throw stones in glass houses 'Furthermore, we are accelerating our collaborative work to fully demonstrate the value of our encapsulation technology in the conventional pesticide industry thereby unlocking numerous high value opportunities in both existing and, critically, new crop targets such as wheat, soybean and cotton'.
Sain@vision, you know the more I look at this statement from the results, I think Eden are saying that Sumiagro and Sipcam have agreed to change legacy agreements and to the 'sale of product' model. Would you agree? 'Going forward, this percentage should continue to increase as the percentage of revenue derived from existing partners has almost fully transitioned to supply and/or distribution agreements (rather than licence agreements)'.
Can't disagree with you sain@vision 'Advantageous agreements wont be given up easily by the other parties' but it looks to me from the statement in the Preliminary Results that the transition of 'legacy agreements' is going on now which is expected to be completed in time for the 2018 growing season and the statement does say 'existing patners' so it would not be to presumptuous to believe that legacy agreements with existing partners like Sumiagro and Sipcam are being or have been renegotiated. 'As a reflection of the change in the Company's business model, approximately 41% of the Company's revenue was derived from the sale of products, rather than licence-based royalties and up-front or milestone payments. Going forward, this percentage should continue to increase as the percentage of revenue derived from existing partners has almost fully transitioned to supply and/or distribution agreements (rather than licence agreements). It is important to note that the transition of certain legacy agreements (from licensing to product sales) had not been completed with some partners by the end of 2017, but we expect this to be completed in time for the 2018 growing season'.
That's a fair point sain@vision regarding Sumiagro, they may have been on the back foot at the time but that's an assumption not a fact. They say they are transitioning from some of the legacy agreements which could include Sumiagro or not, again we don't know for sure. In any case Sumiagro is only Eden's distributor in France I think so although an important income stream now it's importance as Sipcam and other distributors grow sales will be a smaller piece of a growing pie that will within a short time include Bayer, Terpene Tech and Eastman .
From what Gemstar said It sounds like their was No mention of TT or Bayer and had no statement or appreciation of the potential growth in revenue that Mevalone offers by ignoring the underlying commentary. This is a major omission in my view. One can only hope that in future reports he manages to present a less biased and more balanced picture. I for one would welcome that.
Thankyou Gemstar. So in all fairness it sounds like he could have drawn readers attention to the positive reception that Mevalone has recieved and the potential growing revenue, a point that Sean Smith made in the interview, that this will be the first season that the top 3 wine producers plus portugal have Mevalone approval, but chose not to . He could also have also spoken about the TT & Bayer products that may add to the bottom line. But again he chose not to which is a shame as like you say he looks at p&l acs and balance sheets but in Eden's case fails to consider the bigger picture which if this were another share he had backed you can bet he would have.
Does he give any comment on the pipeline of revenue that Eden anticipate from growing Mevalone sales along with the Bayer & TT products? Also both previous times TW has predicted a placing it has resulted in a new Strategic patner stepping in and not only strenghtening Eden's balance sheet but as in the case of Sipcam providing as Sean Smith says a valuable industry partner with aligned interests and wide global reach so doubly advantages Eden.
Smith said they had �3.7m in the Bank with a �1.4m annual burn rate. With revenues increasing I don't see a placing happening, at least not in the next couple of years and by then 2020 the whole picture changes with the opening up of revenue streams from Eastman and Bayer and the new US partner he mentioned to compliment what I expect will be a growing revenue stream from Mevalone sales.
Good Interview. They seem to be thinking about the PR side of things now. I thought the London Live show was also interesting. https://twitter.com/LondonLive/status/976413223086796800